

A clean version of the rewritten or added paragraphs with instruction for entry pursuant to 37 C.F.R. § 1.121(b)(1)(ii) is included beginning on page four of this communication. A marked-up version of the rewritten paragraphs pursuant to 37 C.F.R. § 1.121(b)(1)(iii) is attached as Appendix III.

CLEAN VERSION OF REWRITTEN OR ADDED CLAIMS
PURSUANT TO 37 CFR § 1.21 (c)(1)(i)

Please substitute the following Claim for previously pending Claim 4:

B₁
4. A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 4.

Please cancel Claims 26, 27, 28, 30, 31, 32, 34, 35, and 36.

Please add the following new claims:

B₂
38. The purified antibody of Claim 4, wherein said portion comprises at least 20 amino acids of SEQ ID NO: 4.

39. The purified antibody of Claim 4, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

40. The purified antibody of Claim 4, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

41. The purified antibody of Claim 5, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

42. The purified antibody of Claim 5, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

43. The purified antibody of Claim 6, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

44. The purified antibody of Claim 6, wherein SEQ ID NO: 4 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

45. A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence of SEQ ID NO: 5.

46. The purified antibody of Claim 45, wherein said antibody is a polyclonal antibody.

47. The purified antibody of Claim 45, wherein said antibody is a monoclonal antibody.

48. The purified antibody of Claim 45, wherein said portion comprises at least 20 amino acids of SEQ ID NO: 5.

49. The purified antibody of Claim 45, wherein SEQ ID NO: 5 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

50. The purified antibody of Claim 45, wherein SEQ ID NO: 5 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

51. The purified antibody of Claim 46, wherein SEQ ID NO: 5 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

52. The purified antibody of Claim 46, wherein SEQ ID NO: 5 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

53. A purified antibody which is generated against a polypeptide comprising at least a portion of the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2.

54. The purified antibody of Claim 53, wherein said antibody is a polyclonal antibody.

55. The purified antibody of Claim 53, wherein said antibody is a monoclonal antibody.

56. The purified antibody of Claim 53, wherein said portion comprises at least 20 amino acids of the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2.

57. The purified antibody of Claim 53, wherein the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

58. The purified antibody of Claim 53, wherein the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

59. The purified antibody of Claim 54, wherein the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the carboxy-terminus.

B2
60. The purified antibody of Claim 54, wherein the amino acid sequence encoded by nucleic acid sequence of SEQ ID NO: 2 comprises a carboxy-terminus and an amino-terminus, wherein said portion comprises at least 20 amino acids from the amino-terminus.

CLEAN VERSION OF REWRITTEN OR ADDED PARAGRAPHS
PURSUANT TO 37 C.F.R. § 1.121(b)(1)(ii)

Please add the following paragraph beginning on page 1, line 1, with the following text:

B3
This application is a continuation of International Application PCT/US98/27400, with an international filing date of December 23, 1998, published in English under PCT Article 21(2) and now abandoned. This application claims priority to Provisional Application Ser. No. 60/068,890 filed on December 23, 1997.

On page 58, please delete the paragraph beginning on line 21 and ending on line 28, and replace with the following paragraph:

B4
Construction of LAT in expression vector and mutagenesis: The myc tag was fused to the C-terminus of LAT by replacing the *Pst* I/*Hind* III fragment of LAT in pBluescript (SK-) (Stratagene) with a double stranded oligonucleotide fragment encoding the myc tag sequence (SMEQKLISEEDLN) (SEQ ID NO:16). Flag-tagged LAT was constructed by replacing the *Pst* I/*Cla* I fragment of LAT in pBluescript with a double stranded oligonucleotide fragment encoding the FLAG sequence (DYKDDDDK) (SEQ ID NO:17). The tagged LAT cDNAs were cloned into the pcDNA3 (Invitrogen) or pEF/BOS vector (See Schematic B, and Mizushima and Nagata *et al.*, *Nuc. Acid Res.*, 18: 5322, 1990).

On page 62, please delete the paragraph beginning on line 4 and ending on line 10, and replace with the following paragraph:

B5
Mutagenesis and Subcloning: Cysteine to alanine mutations (position 26 and 29) of LAT cloned into the pCEFL expression vector (a gift from Dr. S. Gutkind, NIDR, NIH) were made with the Stratagene Quickchange kit. The LAT transmembrane domain deletion mutant (residues 1-22) was made by cloning a double-stranded linker annealed with two oligonucleotides (AATTCGCCGCCATGGCACTGTGTG (SEQ ID NO:18) and TGCACACACAGTGCCATGGCGGCG) (SEQ ID NO:19), *Apa* I/*Xba* I fragment from pEF/LAT-myc into pCEFL *Eco* RI/*Xba* I sites.